• Not yet recruiting

NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

Updated: Sep 8

NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma


ABBV-383

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma


Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), daratumumab-dexamethasone (Dd), or nirogacestat (Niro) in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed.


Sponsor

TeneoOne Inc.

Abbvie


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT05259839


Official Title: A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma


First Posted : March 2, 2022


Click here to see details on ClinicalTrials.gov

 

Drug: ABBV-383

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Pomalidomide

Drug: Nirogacestat

Drug: Daratumumab


ABBV-383 (formerly TNB-383B)

TNB-383B

anti-alpha BCMA/anti-alpha CD3 T-cell engaging bispecific antibody TNB-383B

 

* TNB-383B

* anti-BCMA x aCD3 T-BsAb TNB-383B

* anti-BCMA x aCD3 T-cell engaging bispecific antibody TNB-383B

 

Jun 24, 2021, 08:00 ET: AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

Click here for details

 

Locations

United States, Arkansas

United States, Florida

United States, Maryland

United States, Michigan

United States, Montana

United States, New Jersey

United States, North Carolina

United States, Texas

United States, Utah

United States, Washington


Europe

Germany

Italy

Spain

Poland





Posts Archive